Healthcare :: Delivering high quality care for all, UK

Delivering the highest quality of care for all, as good or better than any country in the world, must be a fundamental goal of the NHS, said Lord Darzi, as he publishes his interim report on the ‘Our NHS, Our Future’ review.

Drug Safety :: Lilly’s CEO Calls for Reform of Nation’s Drug Safety System

Sidney Taurel, chairman and chief executive officer, Eli Lilly and Company (NYSE: LLY), in a speech at the Cleveland Clinic, called on the health care industry, medical community and U.S. government to actively collaborate on a health information technology system that would provide more rapid and useful insights on the effectiveness of medicines while improving drug safety.

Eczema :: Specialized bath products for allergic eczema

Specialised bath products to relieve the symptoms of allergic (atopic) eczema are of “questionable” value, says the Drug and Therapeutics Bulletin (DTB). The NHS forks out more than £16 million a year on bath emollients, equivalent to almost 40% of the total cost of eczema treatments prescribed for pre-school children, says DTB.

Genetic :: First significant genetic finding in severe PMS, or PMDD

The first significant genetic finding in premenstrual dysphoric disorder (PMDD) has now been reported. PMDD is a very severe form of the more commonly known premenstrual syndrome, or PMS. PMDD is heritable, affects 5-8% of women, and is associated with severe emotional and physical problems, such as irritability, marked depressed mood, anger, headaches, weight gain and more, to such an extent that quality of life is seriously impacted.

Head Lice :: Bug Buster Kits reduce head lice and social stigma

Working with parents and schools to provide a bug busting approach to head lice is helping to reduce infestation levels, tackle health inequalities and reduce healthcare costs, according to a review in the October issue of Journal of Clinical Nursing.

Pharmaceutical :: MIT and Novartis in new partnership aimed at transforming pharmaceutical manufacturing

Novartis and the Massachusetts Institute of Technology have launched a long-term research collaboration aimed at transforming the way pharmaceuticals are produced. The 10-year partnership, known as the Novartis-MIT Center for Continuous Manufacturing, will work to develop new technologies that could replace the conventional batch-based system in the pharmaceuticals industry – which often includes many interruptions and work at separate sites – with continuous manufacturing processes from start to finish.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack